The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures ...
One class of drugs has already found success in treating the painful, disorienting and common attacks. Excitement is building about a slew of additional drug targets.